SCHEMBL78897

SCHEMBL78897

C1C[C](C2CC2)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2804942 0.92
SCHEMBL9297588 0.89 KMT2A (0.32)
SCHEMBL2325814 0.89
SCHEMBL9297274 0.89 KMT2A (0.32)
SCHEMBL315853 0.89
SCHEMBL28469255 0.89 KMT2A (0.32)
SCHEMBL1524586 0.89
SCHEMBL8493091 0.86 NISCH (0.32)
SCHEMBL435761 0.86 NISCH (0.32)
SCHEMBL7534899 0.86 NISCH (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2018 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118339151-A Compound for inhibiting or degrading BRD9, composition and pharmaceutical application thereof 西藏海思科制药有限公司 2024-07-12 CN claimed
EP-4384520-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND Uppthera, Inc. (KR) 2024-06-19 EP claimed
CN-118146224-A Nitrogen-containing tricyclic derivative and application thereof in medicine 西藏海思科制药有限公司 2024-06-07 CN claimed
CN-117897385-A Compound for degrading Bcl-2 family proteins and application of compound in medicine 西藏海思科制药有限公司 2024-04-16 CN claimed
US-20240109836-A1 NON-HALLUCINOGENIC ARIADNE ANALOGS FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2024-04-04 US claimed
WO-2024073601-A2 ARIADNE AND ANALOGS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROMUSCLAR DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2024-04-04 WO claimed
CN-117801107-A Benzazepine derivatives, conjugates containing same and application thereof 上海迪诺医药科技有限公司 2024-04-02 CN claimed
CN-117720517-A AR inhibitor, composition thereof and pharmaceutical application thereof 西藏海思科制药有限公司 2024-03-19 CN claimed
CN-117597331-A Substituted heterobicyclic derivatives as MGLU7 receptor negative allosteric modulators 阿德克斯法尔马股份公司 2024-02-23 CN claimed
CN-117425646-A Phosphono derivative, composition thereof and pharmaceutical application thereof 西藏海思科制药有限公司 2024-01-19 CN claimed
EP-1009738-A1 SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2000-06-21 EP claimed
EP-0960108-A1 MATRIX METALLOPROTEINASE INHIBITORS PHARMACIA &amp; UPJOHN S.p.A. (IT) 1999-12-01 EP claimed
WO-1999015500-A1 SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1999-04-01 WO claimed
WO-1998033788-A1 MATRIX METALLOPROTEINASE INHIBITORS PHARMACIA & UPJOHN S.P.A. (IT) 1998-08-06 WO claimed
EP-0604885-B1 Liquid crystal display device HOECHST AG (DE) 1997-12-10 EP claimed
WO-1996035680-A1 SULPHONYLAMINO(THIO)CARBONYLTRIAZOLIN(THI)ONES WITH ARYLOXY OR ARYLTHIO SUBSTITUENTS BAYER AKTIENGESELLSCHAFT (DE) 1996-11-14 WO claimed
WO-1995011898-A1 CONDENSED PYRIDINE TYPE MEVALONOLACTONE INTERMEDIATE AND PROCESS FOR ITS PRODUCTION NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1995-05-04 WO claimed
EP-0539976-A1 Ethynyl-alanine-amino-diol compounds for treatment of hypertension G.D. Searle & Co. (US) 1993-05-05 EP claimed
EP-0535548-A1 Inhibitor of atherosclerotic intimal thickening NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1993-04-07 EP claimed
US-4428937-A OXAPENICILLINS; BETA-LACTAMASE INHIBITORS BEECHAM GROUP LIMITED (GB) 1984-01-31 US claimed